Cotadutide Reference
Educational, not medical advice reference for Cotadutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule note…
Plain English
- What it is
- Cotadutide is an experimental medicine that copies two natural gut hormones at the same time (GLP-1 and glucagon). Acting on both is meant to curb appetite and change how the body handles blood sugar and fat. It was never approved by the FDA.
- What people use it for
- The drug company AstraZeneca tested it in trials for obesity, type 2 diabetes, fatty liver disease, and chronic kidney disease. Because it only ever existed inside studies, any community talk is forward-looking guesswork, and anything sold online as cotadutide is not the real trial medicine.
- What the science shows
- Early human trials (called Phase 2) were small and short. One found a possible drop in a urine protein marker of kidney strain in adults who carried extra weight and had chronic kidney disease, though the result was borderline. The research never reached the large, final-stage trials that would prove lasting benefit and safety.
- The catch
- AstraZeneca stopped developing cotadutide in 2023 and shifted to a different once-weekly version, so this is not an active or available drug. Mild to moderate side effects were common in trials. Since it is not approved and not legally sold outside research, anything marketed as cotadutide is unproven and unregulated.
Reference summary
The Phase 2a CKD trial (Parker 2022 Diab Obes Metab, PMID 35403793) reported reductions in albumin-to-creatinine ratio in adults with overweight or obesity plus chronic kidney disease. Earlier Phase 2 data in type 2 diabetes and obesity were also published. The program was discontinued before reaching Phase 3 outcome trials.
Regulatory and posture
- Categories
- GLP-1, Fat Loss
- Aliases
- MEDI0382, GLP-1 / glucagon dual receptor agonist
- Evidence posture
- human - Phase 2 data exist but AstraZeneca discontinued cotadutide development in 2023.
- Regulatory status
- Investigational. Cotadutide is a GLP-1 / glucagon dual receptor agonist that was in AstraZeneca development for obesity, type 2 diabetes, MASH, and chronic kidney disease. AstraZeneca discontinued the cotadutide program in 2023; active clinical development is no longer ongoing. There is no FDA-approved drug label.
- Content review status
- investigational verified
Selected public sources
- ClinicalTrials.gov cotadutide (MEDI0382) trial search
- PubMed: Parker et al. Diab Obes Metab 2022 - efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, in a randomized phase 2a study (PMID 35403793)
Related tools
- GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
- GLP-1 ramp planner - Preview a linear educational dose-step table.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
- GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
- Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.
For research and educational purposes only. Not medical advice.